$BMEA
Biomea Fusion, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023010312 Filed on March 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.636M $5.737M $4.892M
YoY Change 11.6% 57.22% 52.35%
% of Gross Profit
Research & Development $24.40M $20.54M $12.58M
YoY Change 114.93% 85.24% 140.85%
% of Gross Profit
Depreciation & Amortization $300.0K $181.0K $200.0K
YoY Change 50.0% 20.67% 809.09%
% of Gross Profit
Operating Expenses $30.03M $26.28M $17.47M
YoY Change 83.12% 78.3% 107.16%
Operating Profit -$30.03M -$26.28M -$17.47M
YoY Change 83.12% 78.3% 107.16%
Interest Expense $980.0K $962.0K $216.0K
YoY Change 2782.35% 3462.96% 500.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$29.05M -$25.31M -$17.26M
YoY Change 77.51% 72.09% 105.48%
Income Tax
% Of Pretax Income
Net Earnings -$29.05M -$25.31M -$17.26M
YoY Change 77.51% 72.09% 105.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.98 -$0.86 -$0.59
Diluted Earnings Per Share -$0.98 -$0.86 -$591.1K
COMMON SHARES
Basic Shares Outstanding 29.61M 29.40M 29.17M
Diluted Shares Outstanding 29.59M 29.44M 29.20M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.30M $113.0M $149.6M
YoY Change -47.64% -34.85% -24.65%
Cash & Equivalents $86.30M $111.9M $148.5M
Short-Term Investments $0.00 $1.150M $1.152M
Other Short-Term Assets $2.631M $4.770M $4.505M
YoY Change 18.67% 56.65% 157.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $88.93M $117.8M $154.1M
YoY Change -46.76% -33.27% -23.13%
LONG-TERM ASSETS
Property, Plant & Equipment $6.292M $5.841M $2.997M
YoY Change 117.42% 97.0% 100.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $186.0K
YoY Change -100.0% -95.63%
Other Assets $3.889M $3.496M $1.624M
YoY Change 143.21% 184.23% 651.85%
Total Long-Term Assets $23.71M $11.49M $7.598M
YoY Change 202.35% 25.63% -15.69%
TOTAL ASSETS
Total Short-Term Assets $88.93M $117.8M $154.1M
Total Long-Term Assets $23.71M $11.49M $7.598M
Total Assets $112.6M $129.3M $161.7M
YoY Change -35.59% -30.37% -22.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.329M $6.826M $2.410M
YoY Change 111.13% 413.62% 78.52%
Accrued Expenses $13.02M $11.64M $6.503M
YoY Change 162.29% 311.56% 108.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.77M $19.10M $9.362M
YoY Change 135.8% 311.93% 89.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.74M $1.667M $1.984M
YoY Change 402.34% -27.05% -22.95%
Total Long-Term Liabilities $10.74M $1.667M $1.984M
YoY Change 402.34% -27.05% -22.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.77M $19.10M $9.362M
Total Long-Term Liabilities $10.74M $1.667M $1.984M
Total Liabilities $29.51M $20.77M $11.35M
YoY Change 192.2% 200.03% 50.94%
SHAREHOLDERS EQUITY
Retained Earnings -$160.6M -$131.6M -$83.40M
YoY Change 142.97% 164.57% 272.32%
Common Stock $3.000K $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.13M $108.5M $150.4M
YoY Change
Total Liabilities & Shareholders Equity $112.6M $129.3M $161.7M
YoY Change -35.59% -30.37% -22.81%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022 Q2
OPERATING ACTIVITIES
Net Income -$29.05M -$25.31M -$17.26M
YoY Change 77.51% 72.09% 105.48%
Depreciation, Depletion And Amortization $300.0K $181.0K $200.0K
YoY Change 50.0% 20.67% 809.09%
Cash From Operating Activities -$24.04M -$20.20M -$15.43M
YoY Change 140.58% 27.06% 138.22%
INVESTING ACTIVITIES
Capital Expenditures $2.906M $712.0K -$273.0K
YoY Change 2958.95% -343.0% -64.59%
Acquisitions
YoY Change
Other Investing Activities $1.150M $11.00K $7.648M
YoY Change -94.4% -99.77% 427.08%
Cash From Investing Activities -$1.756M -$701.0K $7.375M
YoY Change -108.59% -115.41% 984.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 201.0K 490.0K 318.0K
YoY Change 548.39% 99.19% -99.79%
NET CHANGE
Cash From Operating Activities -24.04M -20.20M -15.43M
Cash From Investing Activities -1.756M -701.0K 7.375M
Cash From Financing Activities 201.0K 490.0K 318.0K
Net Change In Cash -25.60M -20.41M -7.734M
YoY Change -344.29% 83.84% -105.26%
FREE CASH FLOW
Cash From Operating Activities -$24.04M -$20.20M -$15.43M
Capital Expenditures $2.906M $712.0K -$273.0K
Free Cash Flow -$26.95M -$20.91M -$15.15M
YoY Change 167.12% 34.01% 165.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001840439
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40335
CY2022 dei Entity Registrant Name
EntityRegistrantName
Biomea Fusion, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2520134
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
900 Middlefield Road, 4th Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
980-9099
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2022 dei Trading Symbol
TradingSymbol
BMEA
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
255911000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29608622
CY2022 dei Auditor Firm
AuditorFirmId
34
CY2022 dei Auditor Name
AuditorName
DELOITTE & TOUCHE LLP
CY2022 dei Auditor Location
AuditorLocation
San Francisco, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111899000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145736000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
1150000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
27780000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4770000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3045000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
117819000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
176561000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5841000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2965000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
351000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
351000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
3145000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
1230000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
1876000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2151000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2722000
CY2022Q4 us-gaap Assets
Assets
129307000
CY2021Q4 us-gaap Assets
Assets
185705000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6826000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1329000
CY2022Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
11657000
CY2021Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2743000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
618000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
565000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19101000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4637000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1667000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2285000
CY2022Q4 us-gaap Liabilities
Liabilities
20768000
CY2021Q4 us-gaap Liabilities
Liabilities
6922000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29561554
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29561554
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29115421
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29115421
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
240107000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
228532000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131570000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49742000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
108539000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
178783000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129307000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
185705000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62713000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27996000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3671000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20921000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13671000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1656000
CY2022 us-gaap Operating Expenses
OperatingExpenses
83634000
CY2021 us-gaap Operating Expenses
OperatingExpenses
41667000
CY2020 us-gaap Operating Expenses
OperatingExpenses
5327000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-83634000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-41667000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-5327000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
1806000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
100000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
3000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-81828000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41567000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5324000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81819000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41577000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5324000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271777
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271777
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23858552
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23858552
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10532942
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10532942
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-21000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10192000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
322000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5324000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5169000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
55735000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
254000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6234000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41567000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
178783000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
516000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
723000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10336000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-81828000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
108539000
CY2022 us-gaap Profit Loss
ProfitLoss
-81828000
CY2021 us-gaap Profit Loss
ProfitLoss
-41567000
CY2020 us-gaap Profit Loss
ProfitLoss
-5324000
CY2022 us-gaap Depreciation
Depreciation
691000
CY2021 us-gaap Depreciation
Depreciation
249000
CY2020 us-gaap Depreciation
Depreciation
8000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
571000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
704000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
124000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
10336000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6234000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
322000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-144000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-516000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1725000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2517000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
472000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1915000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1218000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
12000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2960000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
640000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
418000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8914000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2110000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
588000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-565000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-589000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-111000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62417000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35438000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4459000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1030000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3171000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
38492000
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
28371000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8308000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27341000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33355000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10192000
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
55738000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
152753000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1239000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
468000
CY2021 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-36000
CY2020 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
36000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1239000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153185000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65966000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33837000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
84392000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
61456000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146087000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61695000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112250000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146087000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61695000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3216000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
334000
CY2022 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
2537000
CY2020 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
38000
CY2020 bmea Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
29000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111899000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145736000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61695000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
351000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
351000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112250000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146087000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61695000
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
8.84
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131600000
CY2022Q4 bmea Cash Cash Equivalents Restricted Cash And Investments
CashCashEquivalentsRestrictedCashAndInvestments
113400000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to clinical and preclinical accruals, manufacturing accruals, fair value of common stock, stock-based compensation, operating lease right-of-use (ROU) assets and liabilities and income taxes. The Company bases its estimates on its historical experience and also on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></p>
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents and investments. The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. The Company invests in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate notes, commercial paper, and asset backed securities. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded in the balance sheet. The Company’s investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate notes and commercial paper, and places restrictions on the credit ratings, maturities and concentration by type and issuer. The Company has not experienced any losses on its deposits of cash, cash equivalents and investments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span></p>
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
81067
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.37
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
434371
CY2022 bmea Number Of Stand By Letters Of Credit Consisted In Restricted Cash
NumberOfStandByLettersOfCreditConsistedInRestrictedCash
2
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.83
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5341975
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.79
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6875000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1747167
CY2022Q4 bmea Fair Value Asset Level1 To Level2 Transfer Amount
FairValueAssetLevel1ToLevel2TransferAmount
0
CY2022Q4 bmea Fair Value Asset Level2 To Level1 Transfer Amount
FairValueAssetLevel2ToLevel1TransferAmount
0
CY2022Q4 bmea Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2022Q4 bmea Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106835000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106834000
CY2022 bmea Weighted Average Remaining Contractual Maturity For Available For Sale Securities
WeightedAverageRemainingContractualMaturityForAvailableForSaleSecurities
P0M12D
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
141859000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
141849000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6757000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3222000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
916000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
257000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5841000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2965000
CY2022 us-gaap Depreciation
Depreciation
700000
CY2021 us-gaap Depreciation
Depreciation
200000
CY2020 us-gaap Depreciation
Depreciation
8000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.88
CY2022Q4 bmea Accrued Research And Development Materials And Services
AccruedResearchAndDevelopmentMaterialsAndServices
6039000
CY2021Q4 bmea Accrued Research And Development Materials And Services
AccruedResearchAndDevelopmentMaterialsAndServices
1674000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
208000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
170000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4774000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
419000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
636000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
480000
CY2022Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
11657000
CY2021Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2743000
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2021Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7483830
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6168355
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
25000000.0
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4254504
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.89
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1868000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1602909
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.86
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2368000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.931
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.910
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.031
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.25
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.28
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.005
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.005
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.015
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization
0.026
CY2020 bmea Effective Income Tax Rate Reconciliation Llc Loss Prior To C Corp Conversion
EffectiveIncomeTaxRateReconciliationLLCLossPriorToCCorpConversion
-0.177
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.215
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.227
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.043
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12100000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7689000
CY2022Q4 bmea Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
10326000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
411000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
65000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1887000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
675000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1129000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1044000
CY2022Q4 bmea Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
480000
CY2021Q4 bmea Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
599000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1633000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
278000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27966000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10350000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27432000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9730000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
534000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
620000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
82000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
48000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
452000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
572000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
534000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
620000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17700000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9400000
CY2022 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
In general, an “ownership change” will occur if there is a cumulative change in the Company's ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Therefore, certain of the Company's carryforward tax attributes may be subject to an annual limitation regarding their utilization against taxable income in future periods. The Company has performed a Section 382 study and has concluded that ownership changes have occurred
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
112000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
133000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
379000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
111000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
624000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
112000
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Significant Change In Unrecognized Tax Benefits Nature Of Event
SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent
The Company does not expect the unrecognized tax benefits to change significantly over the next twelve months.
CY2022 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
There are currently no pending income tax examinations.
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.054
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
727000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
748000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
771000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
259000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2505000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
220000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2285000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
618000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1667000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2285000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-81828000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41567000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5324000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271777
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271777
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23858552
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23858552
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10532942
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10532942
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5651866
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4754960
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7814760
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11350000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12582000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18242000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20539000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5050000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4892000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5242000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5737000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
16400000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
17474000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
23484000
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
26276000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16400000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17474000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23484000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-26276000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
34000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
216000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
594000
CY2022Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
962000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16366000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17258000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-22890000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-25314000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29126088
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29126088
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29196398
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29196398
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29319042
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29319042
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29441596
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29441596
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3798000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5224000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7886000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11088000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2059000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3211000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4752000
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3649000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
5857000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
8435000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
12638000
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
14737000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5857000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8435000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12638000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-14737000
CY2021Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
5000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
36000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
32000
CY2021Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
27000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5852000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8399000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12606000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-14710000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11964205
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11964205
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25161038
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25161038
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29001213
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29001213
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29061076
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29061076

Files In Submission

Name View Source Status
0000950170-23-010312-index-headers.html Edgar Link pending
0000950170-23-010312-index.html Edgar Link pending
0000950170-23-010312.txt Edgar Link pending
0000950170-23-010312-xbrl.zip Edgar Link pending
bmea-20221231.htm Edgar Link pending
bmea-20221231.xsd Edgar Link pending
bmea-ex21_1.htm Edgar Link pending
bmea-ex23_1.htm Edgar Link pending
bmea-ex31_1.htm Edgar Link pending
bmea-ex31_2.htm Edgar Link pending
bmea-ex32_1.htm Edgar Link pending
bmea-ex32_2.htm Edgar Link pending
bmea-20221231_def.xml Edgar Link unprocessable
bmea-20221231_pre.xml Edgar Link unprocessable
bmea-20221231_cal.xml Edgar Link unprocessable
bmea-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bmea-20221231_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
img3250979_0.jpg Edgar Link pending
img3250979_1.jpg Edgar Link pending
img3250979_10.jpg Edgar Link pending
img3250979_11.jpg Edgar Link pending
img3250979_12.jpg Edgar Link pending
img3250979_13.jpg Edgar Link pending
img3250979_14.jpg Edgar Link pending
img3250979_15.jpg Edgar Link pending
img3250979_16.jpg Edgar Link pending
img3250979_17.jpg Edgar Link pending
img3250979_18.jpg Edgar Link pending
img3250979_19.jpg Edgar Link pending
img3250979_2.jpg Edgar Link pending
img3250979_20.jpg Edgar Link pending
img3250979_21.jpg Edgar Link pending
img3250979_22.jpg Edgar Link pending
img3250979_23.jpg Edgar Link pending
img3250979_24.jpg Edgar Link pending
img3250979_25.jpg Edgar Link pending
img3250979_26.jpg Edgar Link pending
img3250979_27.jpg Edgar Link pending
img3250979_28.jpg Edgar Link pending
img3250979_29.jpg Edgar Link pending
img3250979_3.jpg Edgar Link pending
img3250979_30.jpg Edgar Link pending
img3250979_31.jpg Edgar Link pending
img3250979_32.jpg Edgar Link pending
img3250979_33.jpg Edgar Link pending
img3250979_34.jpg Edgar Link pending
img3250979_35.jpg Edgar Link pending
img3250979_36.jpg Edgar Link pending
img3250979_37.jpg Edgar Link pending
img3250979_38.jpg Edgar Link pending
img3250979_39.jpg Edgar Link pending
img3250979_4.jpg Edgar Link pending
img3250979_40.jpg Edgar Link pending
img3250979_41.jpg Edgar Link pending
img3250979_42.jpg Edgar Link pending
img3250979_43.jpg Edgar Link pending
img3250979_44.jpg Edgar Link pending
img3250979_5.jpg Edgar Link pending
img3250979_6.jpg Edgar Link pending
img3250979_7.jpg Edgar Link pending
img3250979_8.jpg Edgar Link pending
img3250979_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending